GenScript ProBio announced that it has received $220,000,000 in its Series C round of funding led by Legend Capital Management Co., Ltd. on January 18, 2023. The transaction included participation from HighLight Capital, GF Xinde Investment Management Co., Ltd, GL Ventures, Xiamen C&D Inc., Shanghai New Alliance Investment Management Co., Ltd., Huatai Zijin Investment Co. Ltd and China Industrial International Trust Asset Management Limited.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.95 CNY | -3.49% | -0.40% | +3.32% |
Apr. 30 | Xiamen C&D's Q1 Profit Falls 24% | MT |
Apr. 29 | Xiamen C&D Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.32% | 4.13B | |
+61.26% | 94.2B | |
+23.65% | 65.21B | |
+7.21% | 41.71B | |
+33.94% | 32.24B | |
+27.78% | 30.18B | |
+17.81% | 22.53B | |
+15.91% | 17.71B | |
-4.26% | 12.93B | |
+2.07% | 5.9B |
- Stock Market
- Equities
- 600153 Stock
- News Xiamen C&D Inc.
- GenScript ProBio announced that it has received $220 million in funding from a group of investors